Europe’s liver disease crisis has reached a point where experts now want governments to hit alcohol and junk food with sharply higher taxes.

A new report, according to the news signal, calls for tough action to confront what it describes as an “escalating and unsustainable burden” of liver-related illness across the continent. Experts say Europe sees about 284,000 deaths a year from liver disease, and they argue that price policy offers one of the clearest ways to reduce harm. Their message lands with force: products linked to preventable illness should no longer stay cheap while public systems absorb the fallout.

Experts say taxes on alcohol and unhealthy food should rise enough to reflect the heavy costs they impose on health services, the criminal justice system and social services.

Key Facts

  • Experts are urging European governments to raise taxes on alcohol and unhealthy food.
  • The report links the push to roughly 284,000 liver disease deaths each year in Europe.
  • It describes liver-related harm as an escalating and unsustainable burden.
  • Proposed tax increases would aim to cover costs borne by health, justice and social care systems.

The proposal goes beyond a standard public health warning. Reports indicate the authors want taxes set high enough not just to discourage consumption, but also to recover some of the enormous public expense tied to liver-related harm. That framing broadens the debate. This is no longer only about individual choice or medical treatment; it is also about who pays when preventable disease strains hospitals, social services and other state-backed systems.

The politics, however, will prove harder than the economics. Tax rises on everyday consumer goods often trigger fierce backlash, especially when households already feel squeezed. Critics may frame the idea as paternalistic or regressive, while supporters will argue that the current system quietly subsidizes harm by leaving taxpayers to pick up the bill. The report’s intervention suggests health experts want governments to treat liver disease less as a private tragedy and more as a policy failure with measurable costs.

What happens next will test Europe’s appetite for aggressive prevention. Governments can ignore the warning and keep paying for the consequences, or they can use tax policy to push behavior and reshape public health outcomes. The stakes stretch beyond one disease: if ministers act, this debate could become a blueprint for how Europe handles preventable illness, strained health budgets and the true price of products that drive long-term harm.